Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Australian Clinical Labs Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Australian Clinical Labs kazanç ve gelirin sırasıyla yıllık 16.2% ve 4.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 24.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.2%

Kazanç büyüme oranı

16.2%

EPS büyüme oranı

Healthcare kazanç büyümesi	25.6%
Gelir büyüme oranı	4.7%
Gelecekteki özkaynak getirisi	24.9%
Analist kapsamı	Good
Son güncelleme	26 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Kazanç ve Gelir Büyüme Tahminleri

ASX:ACL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	804	48	52	185	7
6/30/2026	764	43	48	179	9
6/30/2025	735	37	44	164	8
6/30/2024	696	24	153	160	N/A
3/31/2024	685	20	150	157	N/A
12/31/2023	674	15	147	154	N/A
9/30/2023	686	26	142	149	N/A
6/30/2023	697	36	137	144	N/A
3/31/2023	757	55	143	154	N/A
12/31/2022	818	73	148	165	N/A
9/30/2022	907	126	206	225	N/A
6/30/2022	996	178	263	284	N/A
3/31/2022	931	156	238	256	N/A
12/31/2021	867	134	214	228	N/A
9/30/2021	757	97	179	191	N/A
6/30/2021	647	60	144	154	N/A
3/31/2021	598	79	N/A	N/A	N/A
12/31/2020	549	98	N/A	N/A	N/A
9/30/2020	520	70	N/A	N/A	N/A
6/30/2020	491	41	92	102	N/A
6/30/2019	448	-11	-13	1	N/A
6/30/2018	379	-9	-4	5	N/A
6/30/2017	340	-24	N/A	5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ACL 'nin tahmini kazanç büyümesi (yıllık 16.2% ) tasarruf oranının ( 2.4% ) üzerindedir.

Kazançlar ve Piyasa: ACL şirketinin kazançlarının (yıllık 16.2% ) Australian pazarından (yıllık 12.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: ACL şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: ACL şirketinin gelirinin (yıllık 4.7% ) Australian pazarından (yıllık 5.6% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ACL şirketinin gelirinin (yıllık 4.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ACL 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 24.9 %)

Australian Clinical Labs Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus EPS estimates fall by 20%

Price target decreased by 7.5% to AU$3.56

Consensus EPS estimates fall by 21%

Price target increased by 7.1% to AU$4.03

Price target decreased by 8.5% to AU$3.76

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin